30 articles for J Lloyd
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Pseudosaccharin amines as potent and selective KV1.5 blockers.
Bristol-Myers Squibb Research and Development
Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
Bristol-Myers Squibb Research and Development
Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
Bristol-Myers Squibb
2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents.
Bristol-Myers Squibb
Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.
Bristol-Myers Squibb
N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase.
Pharmaceutical Research Institute
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.
Bristol-Myers Squibb
Pyrano-[2,3b]-pyridines as potassium channel antagonists.
Bristol-Myers Squibb Pharmaceutical Research Institute
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).
Bristol-Myers Squibb Pharmaceutical Research Institute
Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.
Bristol-Myers Squibb Pharmaceutical Research and Development
Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
Bristol-Myers Squibb
Benzopyran sulfonamides as KV1.5 potassium channel blockers.
Bristol-Myers Squibb Pharmaceutical Research Institute
Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Argenta Discovery
Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Argenta Discovery
Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers.
TBA
Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.
Genentech
Identification of Reversible Small Molecule Inhibitors of Endothelial Lipase (EL) That Demonstrate HDL-C Increase In Vivo.
TBA
Structure-Based Design, Synthesis by Click Chemistry and
National Institute of Diabetes and Digestive and Kidney Diseases
Structure-guided development of specific pyruvate dehydrogenase kinase inhibitors targeting the ATP-binding pocket.
University of Texas Southwestern Medical Center
Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease.
University of Waterloo
Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Cornell University
A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides.
University of Toronto